Regression of glomerulosclerosis in subtotally nephrectomized rats: Effects of monotherapy with losartan, spironolactone, and their combination

American Journal of Physiology - Renal Physiology

Volumn 295, Issue 1, 2008, Pages

  Piecha, Grzegorz ^a,b   Koleganova, Nadezda ^a   Gross, Marie Luise ^a   Geldyyev, Aman ^a   Adamczak, Marcin ^b   Ritz, Eberhard ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Aldosterone escape; Renin angiotensin system

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIHYDRALAZINE; LOSARTAN; MINERALOCORTICOID; POTASSIUM; SPIRONOLACTONE; ALDOSTERONE ANTAGONIST; COLLAGEN TYPE 4; DESMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MINERALOCORTICOID RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR AB; PLATELET-DERIVED GROWTH FACTOR AB; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; MONOTHERAPY; MORPHOLOGY; NEPHRECTOMY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REMISSION; STEREOLOGY; TISSUE FIXATION; URINALYSIS; WESTERN BLOTTING; ALBUMINURIA; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG COMBINATION; GLOMERULONEPHRITIS; GLOMERULUS; MALE; PATHOLOGY; SPRAGUE DAWLEY RAT; URINE;

ALBUMINURIA; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; COLLAGEN TYPE IV; DESMIN; DIHYDRALAZINE; DRUG THERAPY, COMBINATION; GLOMERULONEPHRITIS; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; LOSARTAN; MALE; NEPHRECTOMY; NF-KAPPA B; PLATELET-DERIVED GROWTH FACTOR; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 49949116135     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00065.2008     Document Type: Article

References (30)

1. Adamczak M, Gross ML, Amann K, Ritz E. Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol 15: 3063-3072, 2004.
2. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, Ritz E. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14: 2833-2842, 2003.
3. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16: 3306-3314, 2005.
4. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β-1. Nature 346: 371-374, 1990.
5. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Doubleblind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1: 256-262, 2006.
6. El Nahas AM, Bassett AH, Cope GH, Le Carpentier JE. Role of growth hormone in the development of experimental renal scarring. Kidney Int 40: 29-34, 1991.
7. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75, 1998.
8. Fujihara CK, Velho M, Malheiros DMAC, Zatz R. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 67: 1913-1924, 2005.
9. Gardiner P, Schrode K, Quinlan D, Martin BK, Boreham DR, Rogers MS, Stubbs K, Smith M, Karim A. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 29: 342-347, 1989.
10. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: 1063-1068, 1996.
11. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 1: 1054-1065, 2006.
12. Hoffmann S, Podlich D, Hahnel B, Kriz W, Gretz N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 15: 1475-1487, 2004.
13. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 14: 2395-2401, 2003.
14. Liang XB, Ma LJ, Naito T, Wang Y, Madaio M, Zent R, Pozzi A, Fogo AB. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol 17: 1886-1895, 2006.
15. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12, 2004.
16. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 16: 966-976, 2005.
17. Muller DN, Dechend R, Mervaala EMA, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. NF-κB inhibition ameliorates angiotensin ii-induced inflammatory damage in rats. Hypertension 35: 193-201, 2000.
18. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 13: 3005-3015, 2002.
19. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 1084-1093, 2006.
20. Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome. Am J Physiol Renal Physiol 294: F628-F637, 2008.
21. Piecha G, Kokeny G, Nakagawa K, Koleganova N, Geldyyev A, Berger I, Ritz E, Schmitt CP, Gross ML. Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 294: F748-F757, 2008.
22. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237, 1999.
23. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18: 44-49, 2005.
24. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 16: 781-788, 2003.
25. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49: 355-364, 2007.
26. Tokumura T, Muraoka A, Masutomi T, Machida Y. Stability of spironolactone in rat plasma: strict temperature control of blood and plasma samples is required in rat pharmacokinetic studies. Biol Pharm Bull 28: 1126-1128, 2005.
27. Vaziri ND, Bai Y, Ni Z, Quiroz Y, Pandian R, Rodriguez-Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther 323: 85-93, 2007.
28. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-β pathway. Kidney Int 70: 1914-1919, 2006.
29. Yoshida Y, Fogo AB, Ichikawa I. Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 35: 654-660, 1989.
30. Zhang A, Jia Z, Guo X, Yang T. Aldosterone induces epithelialmesenchymal transition via ROS of mitochondrial origin. Am J Physiol Renal Physiol 293: F723-F731, 2007.